CLAIMS

1.- A method for the manufacturing of a composition suitable for forming an *in situ* solid implant in a body comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of from 45:55 to 55:45 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile *in vivo* that makes it suitable to be administered each 4 weeks or even longer periods, characterised in that the method comprises the steps of providing a biocompatible copolymer having an initial polymer weight between 50 and 63 kDa, and then adjusting its molecular weight to between 30 and 46 kDa and its inherent viscosity to a range of 0.25-0.31 dl/g by irradiating it with gamma or beta radiation in the dose range of 10-30 KGy at a temperature higher than -40ºC but lower than 15ºC, wherein the biocompatible copolymer is irradiated in the dose range of 16 to 25 kGy at the temperature of 8ºC.

2.- Method according to claim 1 wherein, when the biocompatible copolymer has an initial molecular weight of 56 kDa, it is irradiated with a radiation dose of 25 KGy to reduce its molecular weight to between 30 and 46 kDa.

3.- Method according to claim 1 wherein, when the biocompatible copolymer has an initial molecular weight of 50 kDa, it is irradiated with a radiation dose of 25 KGy to reduce its molecular weight to between 30 and 40 kDa.

4.- Method according to claim 1 wherein, when the biocompatible copolymer has an initial molecular weight of 63 kDa, it is irradiated with a radiation dose of 30 KGy to reduce its molecular weight to between 30 and 46 kDa.